Docket No. GEN-100D1 Serial No. 10/045,180

In the Claims

1-52 (canceled).

- 53. (previously presented). An isolated polynucleotide encoding a polypeptide selected from the group consisting of:
 - a) a polypeptide comprising the sequence of SEQ ID NO: 3; or
 - b) a polypeptide consisting of a fragment of SEQ ID NO: 3 comprising at least 10 consecutive amino acids of SEQ ID NO: 3; wherein said fragment has at least one biological activity selected from antimicrobial activity or cytotoxic activity.
- 54 (previously presented). The isolated polynucleotide according to claim 53, wherein said polynucleotide encodes a polypeptide consisting of a fragment of SEQ ID NO; 3 comprising at least 15 consecutive amino acids of the polypeptide of SEQ ID NO; 3.
- 55 (previously presented). The isolated polynucleotide according to claim 53, wherein said polynucleotide encodes a polypeptide comprising the sequence of SEQ ID NO: 3.
- 56 (previously presented). The isolated polynucleotide according to claim 53, wherein said polynucleotide encodes a polypeptide consisting of a fragment of SEQ ID NO; 3 comprising at least 10 consecutive amino acids of the polypeptide of SEQ ID NO; 3.
- 57 (previously presented). The isolated polynucleotide according to claim 53, wherein said polynucleotide comprises the sequence of SEQ ID NO:2 or a fragment thereof.

58-60 (canceled).

JMSEN/100DI\Amend-Resp\Amd-final.dod/DNB/s1

Docket No. GEN-100D1 Serial No. 10/045,180

61 (previously presented). The isolated polynucleotide according to claim 54, wherein said polynucleotide encodes a polypeptide comprising a mature peptide consisting of the sequence of SEQ ID NO: 6.

62-70 (canceled).

71 (previously presented). An isolated polynucleotide encoding a polypeptide selected from the group consisting of:

- a) a polypeptide comprising the sequence of SEQ ID NO: 6; and
- b) a polypeptide consisting of a fragment comprising at least 10 consecutive amino acids of the sequence of SEQ ID NO; 6; wherein said fragment has at least one biological activity selected from antimicrobial activity or cytotoxic activity.

72 (previously presented). The isolated polynucleotide according to claim 71, wherein said polynucleotide comprises the sequence of SEQ ID NO:2 or a fragment thereof.

73 (previously presented). The isolated polynucleotide according to claim 71, wherein said polynucleotide encodes a polypeptide comprising the sequence of SEQ ID NO: 6.

74 (canceled).

75 (previously presented). The isolated polynucleotide according to claim 71, wherein said polynucleotide encodes a polypeptide consisting of a fragment comprising at least 10 consecutive amino acids of the sequence of SEQ ID NO: 6.

76 (previously presented). The isolated polynucleotide according to claim 71, wherein said polynucleotide encodes a polypeptide consisting of a fragment comprising at least 15 consecutive amino acids of the sequence of SEQ ID NO: 6.

JAGFN/100D Namend Respland, final.dow/DNB/sl

Docket No. GEN-100D1 Serial No. 10/045,180

77 (previously presented). A vector comprising a polynucleotide encoding a polypeptide selected from the group consisting of:

- a) a polypeptide comprising the sequence of SEQ ID NO: 3; and
- b) a polypeptide consisting of a fragment comprising at least 10 consecutive amino acids of SEQ ID NO: 3; wherein said fragment has at least one biological activity selected from antimicrobial activity or cytotoxic activity.

78 (previously presented). The vector according to claim 77, wherein said polynucleotide comprises the sequence of SEQ ID NO:2 or a fragment thereof.

79 (previously presented). The vector according to claim 77, further comprising elements ensuring the expression of said polynucleotide in a host cell.

80-82 (canceled).

- 83 (previously presented). A vector comprising a polynucleotide encoding a polypeptide selected from the group consisting of:
 - a) a polypeptide comprising the sequence of SEQ 1D NO: 6; and
 - b) a polypeptide consisting of a fragment of SEQ ID NO: 6 comprising at least 10 consecutive amino acids of the sequence of SEQ ID NO: 6; wherein said fragment has at least one biological activity selected from antimicrobial activity or cytotoxic activity.

84 (previously presented). The vector according to claim 83, wherein said polynucleotide comprises the sequence of SEQ ID NO:2 or a fragment thereof.

85 (previously presented). The vector according to claim 83, further comprising elements ensuring the expression of said polynucleotide in a host cell.

JAGEN/100DNAmend ResplAnd.final doc/DNB/st

Docket No. GEN-100D1 Serial No. 10/045,180

86 (previously presented). A host cell transformed with a vector comprising a polynucleotide encoding a polypeptide selected from the group consisting of:

- a) a polypeptide comprising the sequence of SEQ ID NO: 3; and
- b) a polypeptide consisting of a fragment comprising at least 10 consecutive amino acids of SEQ ID NO: 3; wherein said fragment has at least one biological activity selected from antimicrobial activity or cytotoxic activity the group consisting of antimicrobial activity and cytotoxic activity.

87 (previously presented). The host cell according to claim 86, wherein said polynucleotide comprises the sequence of SEQ ID NO:2 or a fragment thereof.

88 (previously presented). The host cell according to claim 86, wherein said vector further comprises elements ensuring the expression of said polynucleotide in said host cell.

89-91 (canceled).

- 92 (previously presented). A host cell comprising a vector comprising a polynucleotide encoding a polypeptide selected from the group consisting of:
 - a) a polypeptide comprising the sequence of SEO ID NO: 6; and
 - b) a polypeptide consisting of a fragment of SEQ ID NO: 6 comprising at least 10 consecutive amino acids of the sequence of SEQ ID NO: 6; wherein said fragment has at least one biological activity selected from antimicrobial activity or cytotoxic activity.
- 93 (previously presented). The host cell according to claim 92, wherein said polynucleotide comprises the sequence of SEQ ID NO:2 or a fragment thereof.
- 94 (previously presented). The host cell according to claim 92, wherein said vector further comprises elements ensuring the expression of said polynucleotide in said host cell.

JAGENI100EHAmend ResplAmil.final.doc/DNIVsI

Docket No. GEN-100D1 Serial No. 10/045,180

95 (previously presented). A method of producing a polypeptide comprising culturing a host cell transformed with a vector comprising a polynucleotide encoding a polypeptide selected from the group consisting of:

- a) a polypeptide comprising the sequence of SEQ ID NO: 3; and
- b) a polypeptide consisting of a fragment of SEQ ID NO: 6 comprising at least 10 consecutive amino acids of SEQ ID NO: 3; wherein said fragment has at least one biological activity selected from antimicrobial activity or cytotoxic activity.

96 (previously presented). The method according to claim 95, wherein said polynucleotide comprises the sequence of SEQ ID NO:2 or a fragment thereof.

97 (previously presented). The method according to claim 95, wherein said vector further comprises elements ensuring the expression of said polynucleotide in said host cell.

98-100 (canceled).

101 (previously presented). A method of producing a polypeptide comprising culturing a host cell transformed with a vector comprising a polynucleotide encoding a polypeptide selected from the group consisting of:

- a) a polypeptide comprising the sequence of SEQ ID NO: 6; and
- b) a polypeptide consisting of a fragment of SEQ ID NO: 6 of at least 10 consecutive amino acids of the sequence of SEQ ID NO: 6; wherein said fragment has at least one biological activity selected from antimicrobial activity or cytotoxic activity.

102 (previously presented). The method according to claim 101, wherein said polynucleotide comprises the sequence of SEQ ID NO:2 or a fragment thereof.

103 (previously presented). The method according to claim 101, wherein said vector further comprises elements ensuring the expression of said polynucleotide in said host cell.

JAGEN/100D (\Amen(FResp\Amd,final,doo'DNT)/sf

Docket No. GEN-100D1 Serial No. 10/045,180

104-105 (canceled).